vs
科睿唯安（CLVT）与泰尼特医疗（HCSG）财务数据对比。点击上方公司名可切换其他公司
科睿唯安的季度营收约是泰尼特医疗的1.3倍（$585.5M vs $466.7M），泰尼特医疗同比增速更快（6.6% vs -1.4%），科睿唯安自由现金流更多（$78.9M vs $16.0M），过去两年泰尼特医疗的营收复合增速更高（5.0% vs -5.1%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
泰尼特医疗集团是一家总部位于达拉斯的美国上市营利性跨国医疗服务企业，旗下通过品牌、子公司、合资企业及合作项目（包括联合外科合作伙伴国际USPI），运营着65家医院与超450家医疗机构，此外还经营康尼弗医疗解决方案，为医疗系统及其他客户提供医疗配套服务支持。
CLVT vs HCSG — 直观对比
营收规模更大
CLVT
是对方的1.3倍
$466.7M
营收增速更快
HCSG
高出8.0%
-1.4%
自由现金流更多
CLVT
多$62.9M
$16.0M
两年增速更快
HCSG
近两年复合增速
-5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $585.5M | $466.7M |
| 净利润 | $-40.2M | — |
| 毛利率 | 67.2% | 15.4% |
| 营业利润率 | 5.2% | 6.1% |
| 净利率 | -6.9% | — |
| 营收同比 | -1.4% | 6.6% |
| 净利润同比 | 61.3% | — |
| 每股收益（稀释后） | $-0.06 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTHCSG
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $466.7M | ||
| Q3 25 | $623.1M | $464.3M | ||
| Q2 25 | $621.4M | $458.5M | ||
| Q1 25 | $593.7M | $447.7M | ||
| Q4 24 | $663.0M | $437.8M | ||
| Q3 24 | $622.2M | $428.1M | ||
| Q2 24 | $650.3M | $426.3M |
净利润CLVTHCSG
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | — | ||
| Q3 25 | $-28.3M | $43.0M | ||
| Q2 25 | $-72.0M | $-32.4M | ||
| Q1 25 | $-103.9M | $17.2M | ||
| Q4 24 | $-191.8M | — | ||
| Q3 24 | $-65.6M | $14.0M | ||
| Q2 24 | $-304.3M | $-1.8M |
毛利率CLVTHCSG
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | 15.4% | ||
| Q3 25 | 65.0% | 20.8% | ||
| Q2 25 | 67.2% | 0.6% | ||
| Q1 25 | 65.1% | 15.2% | ||
| Q4 24 | 65.7% | 13.4% | ||
| Q3 24 | 66.2% | 14.8% | ||
| Q2 24 | 67.2% | 9.7% |
营业利润率CLVTHCSG
| Q1 26 | 5.2% | — | ||
| Q4 25 | 6.7% | 6.1% | ||
| Q3 25 | 7.1% | 12.3% | ||
| Q2 25 | 1.1% | -9.1% | ||
| Q1 25 | -3.5% | 5.3% | ||
| Q4 24 | -9.4% | 3.4% | ||
| Q3 24 | 3.5% | 4.4% | ||
| Q2 24 | -36.9% | -0.5% |
净利率CLVTHCSG
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | -4.5% | 9.3% | ||
| Q2 25 | -11.6% | -7.1% | ||
| Q1 25 | -17.5% | 3.8% | ||
| Q4 24 | -28.9% | — | ||
| Q3 24 | -10.5% | 3.3% | ||
| Q2 24 | -46.8% | -0.4% |
每股收益（稀释后）CLVTHCSG
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $0.43 | ||
| Q3 25 | $-0.04 | $0.59 | ||
| Q2 25 | $-0.11 | $-0.44 | ||
| Q1 25 | $-0.15 | $0.23 | ||
| Q4 24 | $-0.27 | $0.15 | ||
| Q3 24 | $-0.09 | $0.19 | ||
| Q2 24 | $-0.46 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $168.0M |
| 总债务越低越好 | $4.3B | — |
| 股东权益账面价值 | $4.8B | $510.2M |
| 总资产 | $10.9B | $794.3M |
| 负债/权益比越低杠杆越低 | 0.89× | — |
8季度趋势，按日历期对齐
现金及短期投资CLVTHCSG
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | $168.0M | ||
| Q3 25 | $318.7M | $177.5M | ||
| Q2 25 | $362.6M | $134.5M | ||
| Q1 25 | $354.0M | $114.8M | ||
| Q4 24 | $295.2M | $107.3M | ||
| Q3 24 | $388.5M | $103.8M | ||
| Q2 24 | $376.4M | $105.6M |
总债务CLVTHCSG
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — |
股东权益CLVTHCSG
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $510.2M | ||
| Q3 25 | $4.9B | $496.0M | ||
| Q2 25 | $5.0B | $477.0M | ||
| Q1 25 | $5.0B | $514.2M | ||
| Q4 24 | $5.1B | $499.9M | ||
| Q3 24 | $5.5B | $488.7M | ||
| Q2 24 | $5.6B | $471.4M |
总资产CLVTHCSG
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $794.3M | ||
| Q3 25 | $11.2B | $804.3M | ||
| Q2 25 | $11.4B | $802.2M | ||
| Q1 25 | $11.5B | $823.0M | ||
| Q4 24 | $11.5B | $802.8M | ||
| Q3 24 | $12.0B | $805.8M | ||
| Q2 24 | $12.1B | $799.7M |
负债/权益比CLVTHCSG
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.83× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.7M | $17.4M |
| 自由现金流经营现金流 - 资本支出 | $78.9M | $16.0M |
| 自由现金流率自由现金流/营收 | 13.5% | 3.4% |
| 资本支出强度资本支出/营收 | 9.5% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $333.9M | $139.2M |
8季度趋势，按日历期对齐
经营现金流CLVTHCSG
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | $17.4M | ||
| Q3 25 | $181.1M | $71.3M | ||
| Q2 25 | $116.3M | $28.8M | ||
| Q1 25 | $171.2M | $27.5M | ||
| Q4 24 | $141.3M | $36.2M | ||
| Q3 24 | $202.9M | $4.3M | ||
| Q2 24 | $126.2M | $16.3M |
自由现金流CLVTHCSG
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | $16.0M | ||
| Q3 25 | $115.5M | $70.0M | ||
| Q2 25 | $50.3M | $27.4M | ||
| Q1 25 | $110.3M | $25.8M | ||
| Q4 24 | $59.1M | $34.8M | ||
| Q3 24 | $126.3M | $2.9M | ||
| Q2 24 | $60.3M | $15.0M |
自由现金流率CLVTHCSG
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | 3.4% | ||
| Q3 25 | 18.5% | 15.1% | ||
| Q2 25 | 8.1% | 6.0% | ||
| Q1 25 | 18.6% | 5.8% | ||
| Q4 24 | 8.9% | 7.9% | ||
| Q3 24 | 20.3% | 0.7% | ||
| Q2 24 | 9.3% | 3.5% |
资本支出强度CLVTHCSG
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | 0.3% | ||
| Q3 25 | 10.5% | 0.3% | ||
| Q2 25 | 10.6% | 0.3% | ||
| Q1 25 | 10.3% | 0.4% | ||
| Q4 24 | 12.4% | 0.3% | ||
| Q3 24 | 12.3% | 0.3% | ||
| Q2 24 | 10.1% | 0.3% |
现金转化率CLVTHCSG
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | — | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.31× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
HCSG
| Dietary Services | $255.9M | 55% |
| Other | $210.8M | 45% |
